AIDS foundation lobbying Merck on price; Lupin gets FDA nod for generic Topamax; and much more

> In a series of ads, the AIDS Healthcare Foundation is urging Merck to change its pricing and access policies, criticizing an increase of up to six times the price of its anti-HIV drug Stocrin in Mexico than in other Latin American countries. Report

> India's Lupin said it has received tentative FDA approval for its Topiramate tablets, a generic version of the Ortho-McNeil seizure medication Topamax. Report

> AstraZeneca is asking the FDA to broaden the use of injectable Nexium for use in patients with peptic ulcer bleeding following therapeutic endoscopy. Release

> Pharmacopeia said it will cut its workforce by about 15 percent and expects to reduce its annual operating expenditures by at least $10 million in 2009. Report

> India's Dabur Pharma reported a fourfold surge in net profits on robust growth in its oncology business. Report

> Zydus Cadila announced its foray into Spain, the fifth largest pharmaceutical market, through the acquisition of Laboratories Combix for an undisclosed amount. Report

> Bristol-Myers Squibb is adding two oncology drugs to its pipeline with the acquisition of Kosan Biosciences. Report

> An expert panel was underwhelmed by GlaxoSmithKline's data for Promacta, a treatment designed to decrease the frequency and severity of bleeding episodes in people with thrombocytopenic purpura. Report

> New Jersey-based Alfacell took a major hit as it announced that its drug Onconase missed the primary endpoint in a Phase III study. Report

 > San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. Layoff report

And Finally... Solving the mystery of why type 1 diabetes is so prevalent in Finland could be the key to teasing out the causes of the disease. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.